According to a recently published report, the global Orphan Drugs Market is expected to grow $205700 milliontill 2022with the CAGR of 12.6% during 2015-2022. The segmentation of global orphan drugs market is based on therapeutic, type, and regional outlook. The report on global orphan drugs market forecast 2015-2022 (type, therapeutic, and regional outlook) provides a detailed overview and predictive analysis of the market.
Full report available global orphan drugs market forecast 2015-2022 (therapeutic area, type, and regional outlook)report at http://www.briskinsights.com/report/orphan-drugs-market
The global orphan drugs market is growing with the growth of rising rare diseases.Orphan diseases are rare in nature which means its occurrence rate is very low,but its prevalence rate is expected to increase in the forecasted period thereby increasing the demand of global orphan diseases market. There are around 7000 rare types of rare diseases and disorders, these numbers are increasing day by day. 80% of rare diseases are genetically originated and rest are result of infections, environmental causes and allergies. Around 50% of genetic diseases are in children’s, 30 % of children’s with rare diseases cannot live for more than 5 years. There are many types of rare diseases like Rare Cancer, Cystic Fibrosis, Apert syndrome, Batten disease, Crouzon Syndrome, Williams Syndrome and many more. Rare diseases are one of the life threatening diseases that kills millions of lives worldwide. Orphan drugs are the pharmaceutical agent that is specially developed for rare diseases. The prevalence rate of rare diseases are growing at a faster rate, the result in growing need of drugs to cure that diseases. The orphan drugs like Albenza, Proleukin, Ceredase,Zyloprim, Agrylin etc., and these drugs are developed by the pharmaceutical industries to cure the rare diseases.
Scope of the report
1. GLOBAL ORPHAN DRUGS MARKET by type 2012 – 2022 ($ million)
1.2. Non biological
2. GLOBAL ORPHAN DRUGS MARKET by therapeutic 2012 – 2022 ($ million)
3. GLOBAL ORPHAN DRUGS MARKET regional outlook 2012-2022 ($million)
3.1. North America
3.3. Asia Pacific
3.4. Rest of the world
4. Company profiles
4.2. Acorda Therapeutics
4.3. Actelion Pharmaceuticals Ltd.
4.4. Aegerion Pharmaceuticals
4.5. Alexion Pharmaceuticals
4.7. Baxter International
4.8. Bayer Healthcare Pharmaceuticals
4.9. Biomarin Pharmaceutical Inc.
4.10. BoehringerIngelheim GmbH
4.11. Bristol-Myers Squibb
4.12. Cangene Corp.
4.13. F. Hoffmann-La Roche AG
4.14. Johnson & Johnson
4.15. Merck & Co., Inc.
Release ID: 2235